Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morton Coleman

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Epratuzumab: targeting B-cell malignancies through CD22Morton Coleman, David M Goldenberg, Abby B Siegel, et al.
British Journal of Haematology|September 23, 2024
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label studyPaolo Strati, Rebecca Champion, Morton Coleman, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Cancer|March 15, 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapyMorton Coleman, Peter Martin, Jia Ruan, et al.
Acta Haematologica|November 23, 2007
Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individualsY Lynn Wang, Joong W Lee, Jonathan S Kui, et al.
Blood|January 10, 2013
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myelomaAdriana Rossi, Tomer Mark, David Jayabalan, et al.
British Journal of Haematology|December 12, 2024
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)Paolo Strati, Richy Agajanian, Izidore S Lossos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Epratuzumab: targeting B-cell malignancies through CD22Morton Coleman, David M Goldenberg, Abby B Siegel, et al.
British Journal of Haematology|September 23, 2024
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label studyPaolo Strati, Rebecca Champion, Morton Coleman, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Cancer|March 15, 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapyMorton Coleman, Peter Martin, Jia Ruan, et al.
Acta Haematologica|November 23, 2007
Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individualsY Lynn Wang, Joong W Lee, Jonathan S Kui, et al.
Blood|January 10, 2013
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myelomaAdriana Rossi, Tomer Mark, David Jayabalan, et al.
British Journal of Haematology|December 12, 2024
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)Paolo Strati, Richy Agajanian, Izidore S Lossos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Pageof 12